Lykos’ MDMA Trial Conduct Allegations Influence US FDA Advisory Committee

 
• By Bridget Silverman

Safety concerns related to MDMA patient suggestibility and impairment troubled the panel reviewing psychedelic therapy for PTSD, although the FDA advised that therapist misconduct is outside its control.

psychotherapy
The FDA does not regulate psychotherapy. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers